[1] COLEMAN R E.Clinical features of metastatic bone disease and risk of skeletal morbidity[J].Clin Cancer Res,2006,12(20 Pt 2):6243s-6249s.
[2] HERNANDEZ R K,WADE S W,REICH A,et al.Incidence of bone metastases in patients with solid tumors:analysis of oncology electronic medical records in the United States[J].BMC Cancer,2018,18(1):44.
[3] BOXER D I,TODD C E,COLEMAN R,et al.Bone secondaries in breast cancer:the solitary metastasis[J].J Nucl Med,1989,30(8):1318-1320.
[4] THIERY J P,ACLOQUE H,HUANG R Y,et al.Epithelial-mesenchymal transitions in development and disease[J].Cell,2009,139(5):871-890.
[5] KESSENBROCK K,PLAKS V,WERB Z.Matrix metalloproteinases:regulators of the tumor microenvironment[J].Cell,2010,141(1):52-67.
[6] PAGET S.The distribution of secondary growths in cancer of the breast.1889[J].Cancer Metastasis Rev,1989,8(2):98-101.
[7] LIU Y,CAO X.Characteristics and significance of the pre-metastatic niche[J].Cancer Cell,2016,30(5):668-681.
[8] SANTINI D,BARNI S,INTAGLIATA S,et al.Natural history of non-small-cell lung cancer with bone metastases[J].Sci Rep,2015,5:18670.
[9] CETIN K,CHRISTIANSEN C F,JACOBSEN J B,et al.Bone metastasis,skeletal-related events,and mortality in lung cancer patients:a Danish population-based cohort study[J].Lung Cancer,2014,86(2):247-254.
[10] AGUIRRE-GHISO J A.Models,mechanisms and clinical evidence for cancer dormancy[J].Nat Rev Cancer,2007,7(11):834-846.
[11] HONG C F,CHEN W Y,WU C W.Upregulation of Wnt signaling under hypoxia promotes lung cancer progression[J].Oncol Rep,2017,38(3):1706-1714.
[12] AIELLO N M,KANG Y.Context-dependent EMT programs in cancer metastasis[J].J Exp Med,2019,216(5):1016-1026.
[13] KANG Y,PANTEL K.Tumor cell dissemination:emerging biological insights from animal models and cancer patients[J].Cancer Cell,2013,23(5):573-581.
[14] LECHARPENTIER A,VIELH P,PEREZ-MORENO P,et al.Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer[J].Br J Cancer,2011,105(9):1338-1341.
[15] HOU J M,KREBS M,WARD T,et al.Circulating tumor cells as a window on metastasis biology in lung cancer[J].Am J Pathol,2011,178(3):989-996.
[16] WU S,LIU S,LIU Z,et al.Classification of circulating tumor cells by epithelial-mesenchymal transition markers[J].PLoS One,2015,10(4):e0123976.
[17] SCHLIEKELMAN M J,TAGUCHI A,ZHU J,et al.Molecular portraits of epithelial,mesenchymal,and hybrid states in lung adenocarcinoma and their relevance to survival[J].Cancer Res,2015,75(9):1789-1800.
[18] ZACHARIAS M,BRCIC L,EIDENHAMMER S,et al.Bulk tumour cell migration in lung carcinomas might be more common than epithelial-mesenchymal transition and be differently regulated[J].BMC Cancer,2018,18(1):717.
[19] DONG J,HU Y,FAN X,et al.Single-cell RNA-seq analysis unveils a prevalent epithelial/mesenchymal hybrid state during mouse organogenesis[J].Genome Biol,2018,19(1):31.
[20] COX T R,RUMNEY R M H,SCHOOF E M,et al.The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase[J].Nature,2015,522(7554):106-110.
[21] XU S,YANG F,LIU R,et al.Serum microRNA-139-5p is downregulated in lung cancer patients with lytic bone metastasis[J].Oncol Rep,2018,39(5):2376-2384.
[22] QI Y,ZHA W,ZHANG W.Exosomal miR-660-5p promotes tumor growth and metastasis in non-small cell lung cancer[J].J BUON,2019,24(2):599-607.
[23] TAVERNA S,PUCCI M,GIALLOMBARDO M,et al.Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway[J].Sci Rep,2017,7(1):3170.
[24] KIM C W,LEE H M,LEE T H,et al.Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin[J].Cancer Res,2002,62(21):6312-6317.
[25] CHEN G,HUANG A C,ZHANG W,et al.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J].Nature,2018,560(7718):382-386.
[26] LIU Y,CAO X.Immunosuppressive cells in tumor immune escape and metastasis[J].J Mol Med (Berl),2016,94(5):509-522.
[27] HIRATSUKA S,GOEL S,KAMOUN W S,et al.Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation[J].Proc Natl Acad Sci U S A,2011,108(9):3725-3730.
[28] LI J,WANG L,CHEN X,et al.CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung cancer[J].Oncoimmunology,2017,6(6):e1320011.
[29] EBRAHEM Q,CHAURASIA S S,VASANJI A,et al.Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo[J].Am J Pathol,2010,176(1):496-503.
[30] LOBB R J,LIMA L G,MOLLER A.Exosomes:key mediators of metastasis and pre-metastatic niche formation[J].Semin Cell Dev Biol,2017,67:3-10.
[31] ZHANG W,BADO I,WANG H,et al.Bone metastasis:find your niche and fit in[J].Trends Cancer,2019,5(2):95-110.
[32] ONKEN J S,FEKONJA L S,WEHOWSKY R,et al.Metastatic dissemination patterns of different primary tumors to the spine and other bones[J].Clin Exp Metastasis,2019,36(6):493-498.
[33] ZHU M,LIU X,QU Y,et al.Bone metastasis pattern of cancer patients with bone metastasis but no visceral metastasis[J].J Bone Oncol,2019,15:100219.
[34] WANG C,SHEN Y,ZHU S.Distribution features of skeletal metastases:a comparative study between pulmonary and prostate cancers[J].PLoS One,2015,10(11):e0143437.
[35] KAKHKI V R,ANVARI K,SADEGHI R,et al.Pattern and distribution of bone metastases in common malignant tumors[J].Nucl Med Rev Cent East Eur,2013,16(2):66-69.
[36] HIRBE A C,MORGAN E A,WEILBAECHER K N.The CXCR4/SDF-1 chemokine axis:a potential therapeutic target for bone metastases?[J].Curr Pharm Des,2010,16(11):1284-1290.
[37] LEE J H,KIM H N,KIM K O,et al.CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis[J].Cancer Res,2012,72(13):3175-3186.
[38] LIANG T,WANG B,LI J,et al.LINC00922 accelerates the proliferation,migration and invasion of lung cancer via the miRNA-204/CXCR4 axis[J].Med Sci Monit,2019,25:5075-5086.
[39] DURUISSEAUX M,RABBE N,ANTOINE M,et al.Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma[J/OL].ERJ Open Res,2017,3(1):00047-2016.doi:10.1183/23120541.00047-2016.
[40] VALENCIA K,ORMAZABAL C,ZANDUETA C,et al.Inhibition of collagen receptor discoidin domain receptor-1(DDR1) reduces cell survival,homing,and colonization in lung cancer bone metastasis[J].Clin Cancer Res,2012,18(4):969-980.
[41] HOSHINO A,COSTA-SILVA B,SHEN T L,et al.Tumour exosome integrins determine organotropic metastasis[J].Nature,2015,527(7578):329-335.
[42] GRIGORYEVA E S,SAVELIEVA O E,POPOVA N O,et al.Do tumor exosome integrins alone determine organotropic metastasis?[J].Mol Biol Rep,2020,47(10):8145-8157.
[43] BROGGINI T,PIFFKO A,HOFFMANN C J,et al.Passive entrapment of tumor cells determines metastatic dissemination to spinal bone and other osseous tissues[J].PLoS One,2016,11(9):e0162540.
[44] RUCCI N,TETI A.Osteomimicry:how the seed grows in the soil[J].Calcif Tissue Int,2018,102(2):131-140.
[45] KOENEMAN K S,YEUNG F,CHUNG L W.Osteomimetic properties of prostate cancer cells:a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment[J].Prostate,1999,39(4):246-261.
[46] YANG C,PAN H,SHEN L.Pan-cancer analyses reveal prognostic value of osteomimicry across 20 solid cancer types[J].Front Mol Biosci,2020,7:576269.
[47] WEILBAECHER K N,GUISE T A,MCCAULEY L K.Cancer to bone:a fatal attraction[J].Nat Rev Cancer,2011,11(6):411-425.
[48] ZHAO G,ZHANG Y,ZHAO Z,et al.MiR-153 reduces stem cell-like phenotype and tumor growth of lung adenocarcinoma by targeting Jagged1[J].Stem Cell Res Ther,2020,11(1):170.
[49] KUO P L,LIAO S H,HUNG J Y,et al.MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein[J].Biochim Biophys Acta,2013,1830(6):3756-3766.
[50] HIRAKI A,UEOKA H,BESSHO A,et al.Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia[J].Cancer,2002,95(8):1706-1713.
[51] DOUGALL W C.Molecular pathways:osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis[J].Clin Cancer Res,2012,18(2):326-335.
[52] FAGET J,CONTAT C,ZANGGER N,et al.RANKL signaling sustains primary tumor growth in genetically engineered mouse models of lung adenocarcinoma[J].J Thorac Oncol,2018,13(3):387-398.
[53] MILLER R E,JONES J C,TOMETSKO M,et al.RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases[J].J Thorac Oncol,2014,9(3):345-354.
[54] HUANG F,CAO Y,WU G,et al.BMP2 signalling activation enhances bone metastases of non-small cell lung cancer[J].J Cell Mol Med,2020,24(18):10768-10784.
[55] ESER P O,JANNE P A.TGFbeta pathway inhibition in the treatment of non-small cell lung cancer[J].Pharmacol Ther,2018,184:112-130.
[56] JOHNSON R W,NGUYEN M P,PADALECKI S S,et al.TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein,an important osteolytic factor in bone metastasis,is independent of canonical Hedgehog signaling[J].Cancer Res,2011,71(3):822-831.
[57] MAITY S,PAI K S R,NAYAK Y.Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance[J].Pharmacol Rep,2020,72(4):799-813.
[58] 北京医学奖励基金会肺癌青年专家委员会,中国胸外科肺癌联盟.肺癌骨转移疹疗专家共识(2019版)[J].中国肺癌杂志,2019,22(4):187-207.
[59] BAE H M,LEE S H,KIM T M,et al.Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis[J].Lung Cancer,2012,77(3):572-577.
[60] PETERS S,CAMIDGE D R,SHAW A T,et al.Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer[J].N Engl J Med,2017,377(9):829-838.
[61] SHAW A T,KIM D W,NAKAGAWA K,et al.Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J].N Engl J Med,2013,368(25):2385-2394.
[62] TOKITO T,SHUKUYA T,AKAMATSU H,et al.Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases[J].Cancer Chemother Pharmacol,2013,71(6):1493-1498.
[63] LI Z Q,YAN H C,GU J J,et al.Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer:a meta analysis of randomized controlled trials[J].Pharmacol Res,2020,160:105194.
[64] YANG X,ZHAO D,LI Y,et al.Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth[J].Thorac Cancer,2020,11(10):2858-2866.
[65] WANG M,CHAO C C,CHEN P C,et al.Thrombospondin enhances RANKL-dependent osteoclastogenesis and facilitates lung cancer bone metastasis[J].Biochem Pharmacol,2019,166:23-32. |
